US FDA's Words Matter: Sharpless Says Injectable Naloxone OK For Community Distribution
Executive Summary
The acting commissioner's statement is intended to clarify "persistent misunderstanding" about the label for the opioid overdose rescue medication's injectable formulation.
You may also be interested in...
US FDA Looking For Senior Leader In New Drugs Office To Oversee Substance Use Disorder Issues
The deputy Office of New Drugs director will have decision-making authority and help shape policy for substance use efforts.
Nasal Naloxone On Brink Of OTC Among Additional Opioid Overdose Options On US FDA's Plate
Upcoming goal dates for Emergent’s Narcan and Harm Reduction Therapeutics’ RiVive will test the US FDA’s efforts to nurture the over-the-counter naloxone switch, followed by decisions on higher strength nasal opioid antagonist products from Opiant and Orexo to address fentanyl and other synthetic opioids.
More Options For Opioid Overdose: Nasal Naloxone On Brink Of OTC Use, While Opiant And Orexo Stay Rx To Counter High-Potency Opioids
Upcoming goal dates for Emergent’s Narcan and Harm Reduction Therapeutics’ RiVive will test the US FDA’s efforts to nurture the over-the-counter naloxone switch, followed by decisions on higher strength nasal opioid antagonist products from Opiant and Orexo to address fentanyl and other synthetic opioids.